Lewy Body Dementia Psychosis

Neurology

Pipeline Programs

Companies

Clinical Trials

2 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

Extreme market concentration: 68% of spending driven by one FXa inhibitor product
Psychiatric and migraine therapies emerging as secondary growth drivers
High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#	Product	Company	Revenue	Share	Stage	Trend	LOE
1	ELIQUIS (apixaban)	Bristol Myers Squibb	$18.3B	68%	Launch	Stable	15.0yr
2	INVEGA SUSTENNA (paliperidone palmitate)	Johnson & Johnson	$1.8B	7%	Peak	Stable	4.7yr
3	BRILINTA (ticagrelor)	AstraZeneca	$692M	3%	Peak	Stable	10.2yr
4	NUPLAZID (pimavanserin tartrate)	Acadia Pharmaceuticals	$596M	2%	Peak	Stable	10.9yr
5	INVEGA TRINZA (paliperidone palmitate)	Johnson & Johnson	$530M	2%	Peak	Stable	15.6yr

#1ELIQUIS

$18.3B

Bristol Myers Squibb·Launch15.0yr

#2INVEGA SUSTENNA

$1.8B

Johnson & Johnson·Peak4.7yr

#3BRILINTA

$692M

AstraZeneca·Peak10.2yr

#4NUPLAZID

$596M

Acadia Pharmaceuticals·Peak10.9yr

#5INVEGA TRINZA

$530M

Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)

$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)

$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)

$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)

$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)

$931M(3%)

emerging growth segment

Immunomodulators (MS)

$747M(3%)

stable with LOE risk

Other mechanisms

$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186

Open Roles

Companies Hiring

Departments

Top Hiring Companies

Takeda

762

Stryker

434

Thermo Fisher Scientific

350

Abbott

302

Johnson & Johnson

252

By Department

Commercial(23%)

$169K

Clinical Operations(11%)

$132K

Engineering(8%)

$199K

IT(4%)

$100K

Manufacturing(3%)

$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Acadia PharmaceuticalsSAN DIEGO, CA

1 program

ACP-204Phase 34 trials

Active Trials

NCT07095465Enrolling By Invitation126Est. Mar 2029

NCT07029581Recruiting180Est. Mar 2028

NCT06194799Enrolling By Invitation752Est. May 2029

+1 more trials

Trial Timeline

Clinical trial activity over time

2023

2024

2025

2026

2027

2028

2029

Acadia PharmaceuticalsACP-204

Clinical Trials (4)

Total enrollment: 2,132 patients across 4 trials

NCT07095465 Acadia PharmaceuticalsACP-204

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Start: Nov 2025Est. completion: Mar 2029126 patients

Phase 3Enrolling By Invitation

NCT06194799 Acadia PharmaceuticalsACP-204

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Start: Apr 2024Est. completion: May 2029752 patients

Phase 3Enrolling By Invitation

NCT06159673 Acadia PharmaceuticalsACP-204

ACP-204 in Adults With Alzheimer's Disease Psychosis

Start: Nov 2023Est. completion: Feb 20281,074 patients

Phase 2/3Recruiting

NCT07029581 Acadia PharmaceuticalsACP-204

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

Start: Aug 2025Est. completion: Mar 2028180 patients

Phase 2Recruiting

Related Jobs in Neurology

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals

2 actively recruiting trials targeting 2,132 patients

1 companies competing in this space

Related Indications

Schizophrenia(743)Multiple Sclerosis(537)Alzheimer's Disease(493)Parkinson Disease(432)Epilepsy(429)Parkinson's Disease(404)Stroke(376)Alzheimer Disease(338)Depression(272)Migraine(264)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.